A randomized, multicenter, open-label, modified dose-ascension, parallel study of the safety, tolerability and efficacy of oral SCIO-469 in patients with myelodysplastic syndromes
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Talmapimod (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- Sponsors Scios
- 29 Aug 2008 Integrated NCT00744432, from clincialtrials.gov: added IDs, patient number.
- 29 Aug 2008 Integrated NCT00744432, from clincialtrials.gov: added IDs, patient number.
- 29 Aug 2008 Status changed from recruiting to completed, from clincialtrials.gov record.